www.praktickelekarenstvi.cz e18 PRAKTICKÉ LÉKÁRENSTVÍ AKTUÁLNÍ FARMAKOTERAPIE Postavení pioglitazonu v moderní léčbě diabetes mellitus 2. typu ditu u pacientů s DM2 a tyto přípravky jsou v rámci doporučení tlačeny na přední místa v léčbě, nelze zapomínat i na lety prověřený pioglitazon, který má k dispozici rovněž data o příznivém ovlivnění kardiovaskulárních komplikací, ale také disponuje daty o příznivém ovlivnění jednotlivých složek metabolického syndromu, což tento efekt pochopitelně umocňu‑ je. Nelze rovněž podceňovat jeho vliv na zlepšení inzulínové rezistence, ochranný vliv na endotel a B‑buňky. Navíc je pioglitazon nyní dostupný i ve formě generických preparátů, což dále léčbu zlevňuje. V neposlední řadě byla zmírněna i preskripční omezení, která nyní neobsahují hranici HbA1c, doporučenou k zahájení léčby. LITERATURA 1. LowWang CC, Hess CN, Hiatt WR, et al. Clinical update: cardiovascular disease in diabetes mellitus: atherosclerotic cardiovascular disease and heart failure in type 2 diabetes melli‑ tus – mechanisms, management, and clinical considerations. Circulation 2016;133:2459-2502. 2. DeFronzo RA. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the mi‑ ssing links: the Claude Bernard Lecture 2009. Diabetologia. 2010;53:1270-1287. 3. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood‑glucose control with sul‑ phonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853. 4. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational stu‑ dy. BMJ. 2000;321:405-412. 5. Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes. 1996 Dec;45(12):1661-9. doi: 10.2337/diab.45. 12. 1661. 6. DeFronzo RA, Inzucchi S, Abdul‑Ghani M, Nissen SE. Pioglitazone: The forgotten, cost‑ ‑effective cardioprotective drug for type 2 diabetes. Diab Vasc Dis Res. 2019;16:133-143. 7. Goldberg RB, Kendall DM, Deeg MA, et al.; GLAI Study Investigators. A comparison of li‑ pid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabe‑ tes and dyslipidemia. Diabetes Care. 2005;28:1547-1554. 8. Alam F, Islam MA, Mohamed M, et al. Efficacy and Safety of Pioglitazone Monotherapy in Type 2 Diabetes Mellitus: A Systematic Review and Meta‑Analysis of Randomised Con‑ trolled Trials. Sci Rep. 2019;9:5389. 9. DeFronzo RA, Tripathy D, Schwenke DC, et al. Pioglitazone for diabetes prevention in im‑ paired glucose tolerance. New Engl J Med. 2011;364:1104-1115. 10. Deeg MA, Buse JB, Goldberg RB, et al.; GLAI Study Investigators. Pioglitazone and rosi‑ glitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. Diabetes Care. 2007;30:2458-2464. 11. https://www.ema.europa.eu/en/documents/product‑information/pioglitazone‑actavis ‑epar‑product‑information_cs.pdf 12. Mazzone T, Meyer PM, Feinstein SB, et al. Effect of pioglitazone compared with gli‑ mepiride on carotid intima‑media thickness in type 2 diabetes: a randomized trial. JAMA. 2006;296:2572-2581. 13. Koshiyama H, Shimono D, Kuwamura N, et al. Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Me‑ tab. 2001;86:3452-3456. 14. Nissen SE, Nicholls SJ, Wolski K, et al. Comparison of pioglitazone vs glimepiride on pro‑ gression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE ran‑ domized controlled trial. JAMA. 2008;299:1561-1573. 15. Nishio K, Sakurai M, Kusuyama T, et al. A randomized comparison of pioglitazone to inhibit restenosis after coronary stenting in patients with type 2 diabetes. Diabetes Care. 2006;29:101-106. 16. Patel D, Walitt B, Lindsay J, Wilensky RL. Role of pioglitazone in the prevention of res‑ tenosis and need for revascularization after bare‑metal stent implantation: a meta‑analy‑ sis. J Am Coll Cardiol Intv. 2011;4:353-360. 17. Althouse AD, Abbott JD, Sutton‑Tyrrell K, et al. Favorable effects of insulin sensitizers per‑ tinent to peripheral arterial disease in type 2 diabetes: results from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Diabetes Care. 2013;36:3269-3275. 18. Dormandy JA, Betteridge DJ, Schernthaner G, et al. PROactive investigators. Impact of peripheral arterial disease in patients with diabetes – results from PROactive (PROactive 11). Atherosclerosis. 2009;202:272-281. 19. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitazone clinical trial in macrovascular events): a randomized controlled trial. Lancet. 2005;366:12791289. 20. Erdmann E, Dormandy JA, Charbonnel B, et al. The effect of pioglitazone on recurrent
RkJQdWJsaXNoZXIy NDA4Mjc=